CVSI: AI 评分 42/100 — AI 分析 (4月 2026)

CV Sciences, Inc. operates as a life science company focused on plant-based dietary supplements and pharmaceutical cannabinoid development. The company's segments include consumer products and specialty pharmaceuticals.

Key Facts: AI Score: 42/100 Sector: Healthcare

公司概况

概要：

CV Sciences, Inc. develops and markets hemp-based CBD products and plant-based dietary supplements under brands like PlusCBD, targeting the nutraceutical, beauty, and pet sectors. It also develops cannabinoid-based pharmaceuticals, positioning itself in both the consumer wellness and specialty drug markets within the healthcare industry.

CVSI是做什么的？

CV Sciences, Inc., established in 2010 and based in San Diego, California, operates as a life science company in North America. Initially known as CannaVest Corp., the company rebranded in January 2016 to reflect its focus on cannabinoid-based products. CV Sciences is structured into two primary segments: Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under various brand names, including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. These products cater to diverse health care sectors, including nutraceuticals, beauty care, specialty foods, and pet products. The company distributes its consumer products through its websites, internet sales channels, select distributors, brick-and-mortar retailers, and e-tailers. The Specialty Pharmaceutical segment is dedicated to the development and commercialization of cannabinoids for treating medical indications. Its lead drug candidate, CVSI-007, combines CBD and nicotine for the treatment of smokeless tobacco use and addiction, representing the company's foray into pharmaceutical applications of cannabinoids. CV Sciences aims to leverage its expertise in both consumer wellness and pharmaceutical development to establish a strong presence in the cannabinoid market.

CVSI的投资论点是什么？

CV Sciences, Inc. presents a speculative investment thesis centered on its dual approach to the cannabinoid market through consumer products and pharmaceutical development. The company's established consumer product lines, generating a gross margin of 47.0%, provide a revenue base to fund its pharmaceutical endeavors. The development of CVSI-007, targeting smokeless tobacco addiction, represents a high-risk, high-reward opportunity. The company's small market capitalization of $0.01 billion and negative P/E ratio of -4.99 indicate substantial risk. Successful clinical trials and subsequent commercialization of CVSI-007 could drive significant value. However, regulatory hurdles, competition, and the need for additional capital are potential risks. Investors should closely monitor clinical trial outcomes, regulatory developments, and the company's ability to maintain market share in the competitive CBD consumer product market.

CVSI在哪个行业运营？

CV Sciences operates within the rapidly evolving cannabis and CBD industry. The market is characterized by increasing consumer acceptance of CBD products for wellness applications and growing interest in cannabinoid-based pharmaceuticals. The industry faces regulatory uncertainty and intense competition from both established players and new entrants. CV Sciences' dual focus on consumer products and pharmaceutical development positions it to capitalize on both the immediate demand for CBD products and the long-term potential of cannabinoid-based therapies. Competitors include companies like AUSAF, AYRWF, AYURF, BQST, and BUDZ, all vying for market share in the cannabis and CBD space.

Drug Manufacturers - Specialty & Generic

Healthcare

CVSI有哪些增长机遇？

Expansion of the PlusCBD product line into new retail channels: CV Sciences can expand its reach by securing partnerships with major retail chains and online marketplaces. The global nutraceutical market is projected to reach $441.7 billion by 2026, offering a significant opportunity for increased sales. Timeline: Ongoing.
Development and commercialization of CVSI-007: Successful clinical trials and regulatory approval of CVSI-007 for smokeless tobacco addiction could create a significant revenue stream. The market for smoking cessation products is estimated at $8.7 billion globally. Timeline: 3-5 years, contingent on clinical trial results and regulatory approvals.
Geographic expansion into international markets: CV Sciences can explore opportunities to expand its consumer product sales into international markets, particularly in Europe and Asia, where the demand for CBD products is growing. The European CBD market is projected to reach $1.5 billion by 2027. Timeline: 2-3 years.
Strategic acquisitions of complementary businesses: CV Sciences can consider acquiring smaller companies with innovative products or technologies in the CBD or nutraceutical space to expand its product portfolio and market reach. The M&A activity in the cannabis industry remains active. Timeline: Opportunistic.
Development of new CBD-based products for specific health conditions: CV Sciences can invest in research and development to create new CBD-based products targeting specific health conditions, such as anxiety, sleep disorders, and pain management. The market for CBD-based health products is expanding rapidly. Timeline: Ongoing.

Market capitalization of $0.01 billion, reflecting its status as a micro-cap company.
Negative P/E ratio of -4.99, indicating that the company is currently unprofitable.
Gross margin of 47.0%, showcasing the potential profitability of its consumer product segment.
Beta of 0.19, suggesting lower volatility compared to the overall market.
Focus on developing CVSI-007, a pharmaceutical drug candidate for smokeless tobacco addiction, highlighting its commitment to innovation.

CVSI提供哪些产品和服务？

Develops and markets plant-based dietary supplements.
Manufactures and sells hemp-based cannabidiol (CBD) products.
Operates in the nutraceutical, beauty care, specialty foods, and pet product sectors.
Sells products through websites, internet sales, distributors, retailers, and e-tailers.
Develops cannabinoid-based pharmaceuticals for medical indications.
Focuses on CVSI-007, a drug candidate for smokeless tobacco addiction.

CVSI如何赚钱？

Develops and manufactures CBD and plant-based products.
Sells products directly to consumers through online channels.
Distributes products through retail partnerships.
Develops pharmaceutical drugs based on cannabinoids.

Consumers seeking plant-based dietary supplements.
Individuals interested in hemp-based CBD products for wellness.
Retailers and distributors in the nutraceutical and beauty industries.
Patients seeking cannabinoid-based pharmaceuticals (future).

Established brand recognition with PlusCBD and other brands.
Proprietary formulations and manufacturing processes.
Focus on both consumer products and pharmaceutical development.
Distribution network through multiple channels.

什么因素可能推动CVSI股价上涨？

Upcoming: Clinical trial results for CVSI-007 in smokeless tobacco addiction treatment.
Ongoing: Expansion of the PlusCBD product line into new retail channels.
Ongoing: Development of new CBD-based products for specific health conditions.
Ongoing: Geographic expansion into international markets.
Ongoing: Potential strategic acquisitions of complementary businesses.

CVSI的主要风险是什么？

Potential: Regulatory changes impacting the CBD market.
Potential: Delays or failures in clinical trials for CVSI-007.
Ongoing: Intense competition in the CBD market.
Ongoing: Limited financial resources and reliance on external funding.
Ongoing: Fluctuations in raw material prices.

CVSI的核心优势是什么？

Established brand presence in the CBD market.
Diverse product portfolio across multiple health sectors.
Dual focus on consumer products and pharmaceutical development.
Proprietary drug candidate CVSI-007.

CVSI的劣势是什么？

Small market capitalization and limited financial resources.
Negative profitability and reliance on external funding.
Dependence on regulatory environment for CBD products.
Limited market share compared to larger competitors.

CVSI有哪些机遇？

Expansion into new geographic markets.
Development of new CBD-based products for specific health conditions.
Strategic partnerships and acquisitions.
Successful commercialization of CVSI-007.

CVSI面临哪些威胁？

Intense competition in the CBD market.
Regulatory uncertainty and potential changes in CBD regulations.
Fluctuations in raw material prices.
Potential delays or failures in clinical trials for CVSI-007.

CVSI的竞争对手是谁？

Australis Capital Inc. — Focuses on cannabis investments and operations. — (AUSAF)
Ayr Wellness Inc. — Multi-state cannabis operator. — (AYRWF)
Aleafia Health Inc. — Cannabis health and wellness company. — (AYURF)
BioQuest Corp — Develops and markets cannabis products. — (BQST)
BUDZ — Unknown differentiation — (BUDZ)

Key Metrics

MoonshotScore: 42/100

Company Profile

CEO: Joseph D. Dowling
Headquarters: San Diego, US
Employees: 47
Founded: 2013

AI Insight

AI analysis pending for CVSI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CV Sciences, Inc. do?

CV Sciences, Inc. operates as a life science company focused on the development, manufacturing, and marketing of plant-based dietary supplements and hemp-based cannabidiol (CBD) products. The company's Consumer Products segment offers a range of CBD products under brands like PlusCBD, targeting the nutraceutical, beauty, and pet sectors. Additionally, the Specialty Pharmaceutical segment is developing CVSI-007, a drug candidate combining CBD and nicotine for the treatment of smokeless tobacco use and addiction. CV Sciences aims to leverage its expertise in both consumer wellness and pharmaceutical development.

What do analysts say about CVSI stock?

As of 2026-03-16, a comprehensive analyst consensus on CVSI stock is unavailable due to its OTC listing and limited coverage. Key valuation metrics, such as the negative P/E ratio, reflect the company's current lack of profitability. Growth considerations center on the successful development and commercialization of CVSI-007 and the expansion of its consumer product lines. Investors should conduct their own due diligence and consider the inherent risks associated with micro-cap OTC stocks in the cannabis industry.

What are the main risks for CVSI?

The main risks for CV Sciences, Inc. include regulatory uncertainty surrounding CBD products, intense competition in the CBD market, and the potential for delays or failures in clinical trials for CVSI-007. The company's limited financial resources and reliance on external funding also pose a risk. As an OTC-listed company, CVSI faces additional risks related to liquidity, disclosure, and regulatory oversight. Investors should carefully consider these risks before investing in CVSI.